Details of the Drug Formulations

General Information of Drug (ID: DM8S6T7)

• Drug Name: Ivosidenib Drug Info
• Synonyms: UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767

Indication

Disease Entry	ICD 11	Status	REF
Acute myeloid leukaemia	2A60	Approved	[1]
Cholangiocarcinoma	2C12.10	Phase 3	[2]
Haematological malignancy	2B33.Y	Phase 1	[3]

• Cross-matching ID:
  PubChem CID: 71657455
  ChEBI ID: CHEBI:145430
  CAS Number: 1448347-49-6
  TTD ID: D07DCG
  ACDINA ID: D01187

Full List of Drug Formulations Containing This Drug

Ivosidenib 250 mg tablet

Company	Formulation ID	FDA Description
Agios Pharmaceuticals	F23205	Colloidal Silicon Dioxide; Croscarmellose Sodium; Hypromellose Acetate Succinate; Magnesium Stearate; Microcrystalline Cellulose; Sodium Lauryl Sulfate; Fd&C Blue 2; Hypromellose; Lactose Monohydrate; Titanium Dioxide; Triacetin

References

• [1] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [2] ClinicalTrials.gov (NCT02989857) Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy) (ClarIDHy). U.S. National Institutes of Health.
• [3] ClinicalTrials.gov (NCT02073994) Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation. U.S. National Institutes of Health.